The present disclosure provides methods and systems for printing a three-dimensional (3D) material. In some examples, a method for printing a 3D biological material comprises providing a media chamber comprising a medium comprising (i) a plurality of cells and (ii) one or more polymer precursors. Next, at least one energy beam may be directed to the medium in the media chamber along at least one energy beam path that is patterned into a 3D projection wherein the x, y, and z dimensions may be simultaneously accessed in accordance with computer instructions for printing the 3D biological material in computer memory, to form at least a portion of the 3D biological material comprising (i) at least a subset of the plurality of cells, and (ii) a polymer formed from the one or more polymer precursors.

The present invention relates to a method of providing a graft scaffold for cartilage repair, particularly in a human patient. The method of the invention comprising the steps of providing particles and/or fibres; providing an aqueous solution of a gelling polysaccharide; providing mammalian cells; mixing said particles and/or fibres, said aqueous solution of a gelling polysaccharide and said mammalian cells to obtain a printing mix; and depositing said printing mix in a three-dimensional form. The invention further relates to graft scaffolds and grafts obtained by the method of the invention.

The present invention aims to provide a meniscus regeneration material having high meniscus regeneration ability. The present invention provides a meniscus regeneration material including a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) and a polypeptide chain (Y′); a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100; the polypeptide chain (Y) includes 2 to 200 tandem repeats of at least one amino acid sequence (X) selected from the group consisting of an amino acid sequence VPGVG (1) set forth in SEQ ID No: 1, an amino acid sequence GVGVP (4) set forth in SEQ ID No: 4, an amino acid sequence GPP, an amino acid sequence GAP, and an amino acid sequence GAHGPAGPK (3) set forth in SEQ ID No: 3; the polypeptide chain (Y′) includes the polypeptide chain (Y) in which 5% or less of amino acid residues are replaced by at least one of a lysine residue and an arginine residue, and a total number of the lysine residue and the arginine residue is 1 to 100; the protein (A) has a total percentage of β-turns and random coils of 60 to 85% as determined by circular dichroism spectroscopy; and when the amino acid sequence (X) in which 60% or less of amino acid residues are replaced by at least one of a lysine residue and an arginine residue is denoted as an amino acid sequence (X′), a ratio of a total number of amino acid residues in the amino acid sequence (X) and the amino acid sequence (X′) in the protein (A) to the number of all amino acid residues in the protein (A) is 50 to 70%.

The present invention relates to a method of manufacturing an animal cartilage-derived injectable composition, an injectable composition manufactured by the method, and a use thereof.

The injectable composition of the present invention includes a collagen-containing biomaterial in a formulation injectable into joint cavity and may induce cartilage tissue regeneration by repairing tissue via direct injection to a target region without surgical incision. In addition, the injectable composition may be used as a therapeutic agent for arthritis by alleviating osteoarthritis not only because the animal cartilage-derived extracellular matrix contained in the injectable composition protects articular cartilage tissue but also because an environment capable of regenerating damaged articular tissue is created by inducing differentiation of intra-articular stem cells into chondrocytes.

A composition has hyaluronic acid and one or more materials as an admixture. The hyaluronic acid is derived from a fascia tissue layer of an alligator, the fascia layer located below a hide and above muscle tissue. The one or more materials as the admixture to the hyaluronic acid can be a carrier, diluent or excipient. The hyaluronic acid is extracted from the fascia tissue layer in the form of an oil having an oily viscosity with a molecular weight of 30,000 or greater. The oil extracted includes the hyaluronic acid and includes sodium or salts of hyaluronic acid. The oil extracted is anti-inflammatory to human tissue.

Therapeutic devices configured to be worn by an individual to apply compression, vibration, and/or heat to cartilage tissue at one or more joints of the individual. The individual dons the therapeutic device so that therapeutic units of the therapeutic device are located in proximity to the cartilage tissue, and electrical power is supplied to a control system and to the therapeutic units to operate and control each of the therapeutic units individually and simultaneously to selectively apply the compression, vibration, and/or heat to the cartilage tissue.

An object of the invention is to provide a cartilage regenerative material that suppresses infiltration of fibrous soft tissue and brings about satisfactory cartilage regeneration, and a method for producing the cartilage regenerative material. Provided is a cartilage regenerative material including a porous body of a biocompatible polymer and a biocompatible polymer film, in which the porous body contains chondrocytes and cartilage matrix, and the cartilage matrix exists in a region of 10% or more of a region extending from the surface of the transplant face of the porous body to a depth of 150 μm along the thickness.

A pre-sutured allograft construct and method of manufacture for repairing, replacing, reconstructing, or augmenting a hip or shoulder labrum may include a folded tissue portion extending from a first end to a second end and forming top, middle, and bottom folds. A stitched pattern secures the folded tissue portion into a graft roll having an overall length extending from a first adjustable region, through a central region, and through a second adjustable region. A continuous series of whip stitches extends from the first adjustable region, through the central region, and through the second adjustable region. A series of triple circumferential stitches overlays the whip stitches in the first and the second adjustable regions, while a series of circumferential stitches alternates with the whip stitches in the central region. The construct is pre-manufactured as an allograft product, but is adjustable during the surgical procedure within the body. Other embodiments are also disclosed.

Polyurethane-based tissue fillers useful for treating and/or augmenting tissue, as well as acting as a biological scaffold that promotes cell in-ingrowth and tissue integration, are disclosed, as are quick-setting, injectable precursors of such tissue fillers. Such tissue fillers generally comprise (1) a polyurethane and (2) a particulate acellular tissue matrix. Also disclosed are methods of treating and/or augmenting tissues using such tissue fillers, particularly voids in human tissue such as anal fistulae or hernias.

Disclosed is a method for differentiating induced pluripotent stem cells (iPSCs) into chondrocytes and integrating them into a matrix/scaffold to provide a cartilage implant. The method comprises the steps of seeding a surface of a substrate with iPSCs. The surface is coated with nanoparticles in a particle density of at least 500 particles/μm2, and parts of the surface in between said nanoparticles are coated with a coating agent. Growth differentiation factor 5 (GDF5) molecules are attached to the nanoparticles. The method further comprises the steps of adding a first differentiation medium to the seeded iPSCs and allowing the seeded iPSCs to differentiate at least into chondrocyte progenitor cells on the surface in the presence of the first differentiation medium. The obtained differentiated cells are integrated into a matrix/scaffold.